Concordance between central and local HER2 testing was 83%. Concordance between PathVysion and IQ PharmDx FISH assays was 99% and FISH in the two central laboratories was 95%. Lapatinib-treated Asian participants and those less than 60 years had significant improvement in progression-free survival (PFS), particularly among those whose cancers had 5.01-10.0 and >10.0-fold amplification of HER2. In conclusion, HER2 is commonly amplified in UGI adenocarcinomas with amplification highly correlated to overexpression, and HER2 amplification levels correlated with PFS. While HER2 genomic heterogeneity occurs, its prevalence is low.
Introduction
The human epidermal growth factor receptor (EGFR) type 2 (HER2) gene (aka ERBB2) is commonly amplified (1) (2) (3) and overexpressed in adenocarcinomas of the stomach, gastroesophageal junction (GEJ) and esophagus and is a potential target for therapeutic intervention. Although the role of HER2 as a prognostic marker in gastric cancer remains an issue of debate, HER2 amplification/overexpression is an important therapeutic target for trastuzumab and is associated with significant improvements in progression-free(PFS) and overall survival(OS) (4) . Routine diagnostic testing is now recommended in gastric and GEJ adenocarcinomas based on these findings that led to approval of the drug by the U.S. Food and Drug Administration(FDA) (5) and European Medicines Agency (EMA).
Here we report on assessments of HER2 status conducted for patient entry to a trial of lapatinib, a dual tyrosine kinase inhibitor of HER2 and EGFR, in combination with chemotherapy in patients with advanced HER2-positive upper gastrointestinal(UGI) adenocarcinomas. The TRIO-013/LOGiC study was based on efficacy of lapatinib in HER2-positive breast cancer patients (6) (7) (8) (9) and activity both in vitro and in vivo with UGI cancer cell lines exhibiting HER2 gene amplification (10) . In addition, modest single-agent activity had been observed in patients with UGI cancers. At the time this trial was initiated no anti-HER2 agent had demonstrated activity in a systematic study of this disease. This retrospective study of HER2 gene amplification and overexpression in UGI adenocarcinomas was initiated to explore the potential roles of HER2 amplification levels and HER2 genomic heterogeneity in lapatinib treatment responsiveness, as measured by improved PFS or improved OS in the LOGiC clinical trial.
Materials and Methods

TRIO-013/LOGiC clinical trial.
The and outcomes are described separately (11) . Here we describe HER2 testing issues and their associations with outcomes. The study was conducted in accordance with the current ethical principles outlined in the Declaration of Helsinki guidelines (12) . cancers to establish a consistent standard for HER2-positivity across the trial based on previous approval as a companion diagnostic for breast cancer patient selection to HER2-targeted therapies and experience with this assay method (8, (13) (14) (15) (16) (17) (18) . Formalin-fixed paraffin-embedded (FFPE) tissues or unstained sections were submitted to a central laboratory for assessment of HER2 status( Figure 1A ). copy number were identified they were scored separately by FISH and the tumor area estimated.
HER2 Status for Enrollment in the TRIO
HER2 amplification was defined as a HER2 gene-to-CEP17 ratio of 2.0 or greater, the U.S. FDA-approved ratio; an average HER2 gene copy number of 4.0 or greater was not required (19) (20) (21) . Similarly for IHC, high geographic variability in HER2 immunostaining (e.g. areas of IHC 3+ and other areas of IHC 0/1+ that are consistent with HER2 genomic heterogeneity) were noted and the percent of each area was estimated (see Figure 2 and Supplementary Figures S1 and S2).
HercepTest IHC Assay. During the conduct of this trial it became apparent, based on reports from ToGA trial investigators (4, 22) , that there may be some controversy related to HER2 testing in gastric and GEJ adenocarcinomas. Therefore, TRIO/CIRG investigators and the trial sponsor decided to also implement immunohistochemistry (IHC) testing for HER2 protein in the central laboratories. The HercepTest(Dako, Inc.), a companion diagnostic initially approved for breast cancer assessments and subsequently, approved for gastric and GEJ adenocarcinomas, was used to determine HER2 protein expression as described (15) (16) (17) and summarized in Supplementary Methods.
Concordance Study. The HER2 PathVysion FISH assay was selected as the primary testing method for assessment of HER2 status; however, during the trial questions were raised about assay comparability with the HER2 IQFISH pharmDx method (Dako Corporation) which became FDA-approved for HER2 testing in gastric cancer for selection of patients to trastuzumab therapy. In order to assess agreement rates between assay methods and agreement rates in the two central laboratories, a separate cohort of 488 UGI adenocarcinoma cases, 419(86%) gastric, 43(8.8%) gastroesophageal junction(GEJ), and 26(5.3%) esophageal cancers, were procured from commercial providers (Asterand Bioscience, Analytical Biological Services, Inc., Proteogenex, Inc., Individumed GmbH) as FFPE blocks and screened by HercepTest to ensure representation of all four IHC staining intensities ( Figure 1B ). All IHC3+ and IHC2+ cases were included in the concordance study. Whereas IHC1+ and IHC 0 cases were grouped by primary tumor site (gastric, GEJ and esophageal) with inclusion of all GEJ and esophageal carcinomas, then gastric carcinomas were randomly selected. The 159 selected cases were masked and sent to two central laboratories for HER2 FISH testing, masked to all information.
Data Analyses. Statistical aspects of the LOGIC study design and statistical methods for analyses are summarized elsewhere (11) . Briefly, we performed a Cox proportional hazards model on treatment for each of the subgroups to compute a hazard ratio and 95% confidence interval. Then using the unstratified log rank test, we computed p-values, as well as median survival times and 95% confidence intervals for both PFS and OS. Although the analyses between FISH results and outcomes reported here are exploratory and hypothesis generating, the differences observed retrospectively in a clinical trial were still considered in our analyses as potentially meaningful, namely, they warrant further exploration in a subsequent study, or not.
We chose a p-value of ≤0.05 as our threshold to suggest a marker / analysis was meaningful. For concordance analyses, positive percent agreement (PPA), negative percent agreement (NPA) and overall percent agreement (OPA) with 95% confidence intervals were determined as described (23) and summarized in Supplementary Methods. laboratories. An additional 33 cases with HER2 genomic heterogeneity were identified among those screened in local laboratories and confirmed in a central laboratory. Demographic data for these patients demonstrates a higher frequency of disease among men and shows that men and older patients have higher rates of HER2 gene amplification (Table 1 ).
Results
HER2
In patients whose cancers were centrally assessed, either for primary assessment or confirmation of local laboratory results, HER2 status by both FISH and IHC is known for 1250 with 457/547(83.5%) amplified cases IHC2+ or IHC3+ and 680/703(96.7%) non-amplified cases either IHC1+ or IHC0 ( Table 2 ). The overall concordance rate between FISH and IHC results for HER2 status was 91% (95% confidence interval{CI}: 89.2%, 92.4%). In our dataset, there were no cases that were IHC3+/FISH-negative. The majority (84%) of IHC2+ cases were HER2 amplified, while relatively few IHC0(n=33, 6%) or IHC1+(n=57, 26%) cancers were HER2 amplified( Table 2 for FISH ratios >5.0-10.0 and the highest distribution (IHC3+{91%}) for FISH ratios >10.0 (Table 2) .
Of 333 patients with trial enrollment based on local laboratory testing, 332 had tumor tissue available for subsequent re-assessment in a central laboratory (Supplementary Table S1 ).
Concordance between central and local HER2 testing was 84.4% (275/326, Figure 1A ). Since samples were not required for re-evaluation in the central laboratory for patients not enrolled to the trial, overall concordance in this population could not be assessed.
The agreement rate between local and central laboratory HER2 testing was dependent on the HER2 testing method used in the local laboratory and concordance varied accordingly.
Among the 332 cancers evaluated both locally and centrally, 259 cases were tested in local laboratories by ISH alone, 33 by ISH and IHC, and 40 by IHC alone. Among the 292 cases tested locally by ISH, the central laboratory determined the HER2 gene amplification status in 286 of the cases. HER2 amplified status was confirmed for 250; however, 36 were assessed as not amplified for an ISH concordance rate of 87% (95% CI: 83.1%, 90.8%)(Supplementary Table S2 ). Seven cases had been evaluated by CISH in local laboratories and five of the cases were confirmed as amplified by central laboratory FISH. Agreement between local laboratory and central laboratory for HER2 IHC assays was even less (58%) (Supplemental Supplementary   Table S3 ), although the number of cases analyzed was limited and different assays may have been used locally (n=73).
Concordance Study for Different HER2 FISH assay methods between the two Central
Laboratories. Before accrual to the LOGiC trial was complete, the ToGA trial was completed and the FDA, subsequently, approved two companion diagnostic assays, the Dako HercepTest IHC assay (October, 2010) and the Dako HER2 IQFISH pharmDx FISH assay (February, 2013) for selection of gastric and GEJ cancer patients to trastuzumab plus chemotherapy (4) . Therefore, we performed a concordance study to demonstrate agreement between the PathVysion HER2 FISH assay and the Dako HER2 IQFISH pharmDx HER2 assay (Figure 1B and Supplementary   Results and Supplementary Tables S4 and S5 ). UGI adenocarcinomas from 488 patients who were not enrolled in the TRIO-013/LOGiC trial were used for the concordance studies ( Figure   1B ). In order to ensure the full spectrum of HER2 expression was more evenly represented in the concordance comparison rather than a predominance of HER2 low-expression, not-amplified Summary of clinical outcomes in the TRIO-013/LOGiC trial. In total, among the 545 patients accrued to the trial, 487 patients had central-laboratory-confirmed HER2 amplified disease to comprise the primary efficacy population (PEP); while 51 had HER2 non-amplified disease and HER2 amplification status was not determined in seven patients (Table 3 and Figure   1A ).
Among the 487 patients with HER2-amplified cancers in the PEP, 424(87.1%) had gastric, 43(8.8%) GEJ and 20(4.1%) esophageal cancers. In the PEP 297 had cancers that were HER2 IHC3+ (61%), 108 were IHC2+ (22%), 54 were IHC1+ (11%), 27 were IHC0 (6%), and one was IHC unknown. As reported separately in detail(11), the LOGiC trial did not meet its primary end-point of a significant improvement in OS among those patients randomized to receive chemotherapy with lapatinib (HR=0.91 {95%CI: 0.73, 1.12}, p-value=0.35); however, a significant improvement in PFS was observed (HR=0.82 {95%CI: 0.68, 1.00}, p-value=0.038).
Subset analyses demonstrated meaningful improvements in both PFS and OS for selected subsets of patients, such as those accrued in Asian countries and those patients less than 60 years of age at trial enrollment (Table 3 and Supplementary Table S6 ). Among Asian participants and those less than 60 years of age we observed greater PFS related to higher levels of HER2 gene amplification (Table 3 ). In the overall trial population (>10.0-fold) as well as among the Asian population (5.01-10.0 and >10.0-fold) and in the population less than 60 years of age the hazard ratio for PFS became more pronounced only at higher levels of HER2 gene amplification (>5.0-10.0 and >10.0 fold)( Table 3) . HER2 ratio was not associated with OS in the overall population or in the sub-populations analyzed for PFS ( participants from Asian countries with HER2-amplified/IHC2+/3+ UGI adenocarcinoma, PFS (HR=0.59; p-value = 0.0020) and OS (HR=0.60, p-value=0.0108) were greatly improved by the addition of lapatinib to chemotherapy. These results were highly intriguing and will be proposed for further prospective assessments in subsequent studies.
Discussion
Gastric cancer remains the third leading cause of cancer-related mortality in the world (24) .
Treatment typically involves gastric resection; however, surgery alone is generally only curative for patients with early-stage disease. For patients with advanced resectable disease, survival rates remain poor but are improved by chemotherapy and possibly radiotherapy (25) (26) (27) .
HER2 amplification/overexpression as a prognostic marker. The majority of gastric cancer studies do not show an association of HER2 status with clinical outcomes in the absence of chemotherapy and/or radiation therapy(28-37); however, studies of patients treated with chemotherapy and/or radiation therapy demonstrate a survival advantage for patients whose gastric cancers lack HER2 gene amplification/overexpression (32, (38) (39) (40) (41) ). An additional large study of patients with adenocarcinomas of the gastric cardia, gastroesophageal junction and esophagus treated by surgical resection (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) showed no difference in either diseasespecific survival or OS among patients whose cancers had HER2 gene amplification(42). The 
potential role of HER2 as a predictive marker of responsiveness to chemotherapy and radiation therapy is supported by a retrospective analysis of HER2 gene amplification and overexpression in gastric cancers from patients in the INT-0116/SWOG9008 phase III gastric cancer clinical trial comparing surgery alone with surgery and chemotherapy (5-fluorouracil)/radiation therapy (13) . Patients whose gastric cancers were HER2-negative and were treated with chemoradiation therapy had a longer disease-free and overall survival than similar patients treated with gastrectomy alone. In contrast, no benefit from chemotherapy and radiation therapy was observed among the subset of patients whose gastric cancers had HER2 amplification/overexpression (13) .
HER2
amplification/overexpression as a target for therapy. HER2
amplification/overexpression is an important therapeutic target for trastuzumab in metastatic gastric and gastroesophageal cancer(4), as it is in metastatic breast cancer (9, 18, 43) . Both the 
Although differences in survival among the overall LOGiC trial population were not observed, Asian patients and patients under 60 years of age did show noticeable improvements in OS(44).
However, we did not find any systematic difference in HER2 status by either immunohistochemistry or FISH among these subgroups that could account for the differences in outcome. Table S3 ); however, the number of cases available for this analysis was quite limited. Overall agreement between HER2 IHC and FISH assays in the central laboratory was approximately 90%, 91% in the LOGiC clinical trial cases (n=1250) and 88% in the concordance cohort cases (n =155). The discrepancies identified for HER2 status determined by IHC compared to FISH, as well as disagreements between local and central laboratory testing, have the potential to inappropriately select some patients for HER2 targeted therapy as well as the potential to inappropriately deny other patients such treatment. Our findings suggest this is of particular concern when IHC is used as the primary test, as addressed elsewhere in detail (20) .
HER2 testing in UGI cancers
There has been some concern that UGI endoscopic biopsies may not provide sufficient tissue for adequate identification of all cancers with this alteration. Although we did not have Figure 2 and Supplementary Figures S1 and S2 ). The rate did not vary significantly by patient age, gender, country, or anatomical site. Although the total number of these cases identified by the central laboratory was modest (n=62), 51 of the cases were identified in patients who were subsequently randomly assigned to study treatment, 24 to the lapatinib treatment arm and 27 to the control arm, no significant differences were observed in PFS or OS. It should be noted that our definition (15) of HER2 genomic heterogeneity differs from the definition used in CAP guidelines(45).
The definition of HER2 genomic heterogeneity used in the LOGiC trial was the same as used for trials of breast cancer screened in the same two TRIO/BCIRG central laboratories (16) for the BCIRG-005(46), BCIRG-006 (8) more than 5% but less than 50% of infiltrating tumor cells with a ratio higher than 2.2." We also differ from the guidelines in our approach to scoring HER2 heterogeneity. According to the guidelines, "if 20 cells are counted and at least one cell is identified with a HER2/CEP17 signal ratio higher than 2.2, this specimen contains GH. Likewise, if 60 cells are examined and 3 or more cells have a ratio higher than 2.2, HER2 GH is present." Using this definition leads to substantially higher rates of HER2 heterogeneity by FISH ranging from 14% to 26% in breast cancers (48, 49) . However, use of the same definition in gastric cardia, gastroesophageal junction and esophagus adenocarcinomas demonstrated only 20 of 675(2.9%) have HER2 genetic heterogeneity(42). These studies contrast with our previously reported lower rates (0.5% and 1.1%) in breast cancer (15, 16, 21) and similarly low rate for UGI cancers reported here. The 62 cases with HER2 genomic heterogeneity were identified in this study with 51 accrued to the trial. Only two of these cases had genomic heterogeneity in a subpopulation of tumor cells representing less than 5% of the total area of the tumor. A limitation of our estimates of HER2 genomic heterogeneity is that we seldom had more than a single tissue block from the primary carcinoma from which to make these evaluations. Therefore, our frequencies should be considered from this perspective.
Association of Lapatinib responsiveness with HER2 amplification level. In breast cancer
clinical trials of lapatinib we have found a relatively uniform hazard ratio for PFS that was independent of HER2 amplification level in HER2-amplified breast cancer patients (15) . Only ratio of 4.7 as the optimal cutoff value discriminating sensitive and refractory patients (P = 0.005); a ratio of 4.45 as the optimal cutoff for survival >12 months (P = 0.005), and a ratio of 5.15 as the optimal cut-off for survival >16 months (P = 0.004) (50) . Although there were only 66 patients in the Ock et al study with HER2 gene amplification status determined by FISH, the conclusions were similar (51) . Neither of these studies have a control, untreated group to confirm that patients with a HER2/CEP17 ratio less than 4.7 lack significant improvement in outcomes; however, patients whose cancers have ratios more than approximately 5 show improved outcomes compared to those whose cancers have lower levels of gene amplification. These findings are consistent with our own findings of greater benefit among patients whose cancers 
have higher levels of amplification (ratio 5.0-10 and >10).
The LOGiC trial did not show a significant association with OS(44), while ToGA did (4) .
LOGiC demonstrated a significant association with PFS but not with the primary end-point of OS. We consider this to be potentially influenced by several issues including 1.) sample size and its influence on statistical power, 2.) differential drug efficacy between lapatinib and trastuzumab and 3.) treatment compliance. Design of the original LOGiC trial was probably slightly underpowered (n=545 in LOGiC compared to 594 in ToGA), since LOGiC was originally based on PFS as the initial primary end-point, which was later changed to an OS primary end-point. After exclusion of patients whose disease was HER2-not-amplified, the PEP was limited to 487 participants. LOGiC might have benefited from enrollment of additional participants to gain statistical power for an association with OS. Second, the differential in median OS favored the In contrast to trastuzumab with the requirement for intravenous administration, lapatinib, an oral medication, was self-administrated by most participants. This introduces the potential for reduced compliance in the lapatinib treatment arm, especially among patients who may have experienced gastrointestinal side-effects. These issues are compounded by our observations, reported here, that HER2 gene amplification levels may impact clinical outcomes.
Finally, we have not analyzed the potential for other concurrent alterations to effect treatment resistance. For example, co-amplification of HER2 and MET is relatively common in esophago-gastric carcinomas (1, 52) and is associated with lack of treatment response to either MET kinase inhibitor (crizotinib) or HER2 inhibitor (trastuzumab) treatment but is associated with therapeutic response to combined treatment in patients with advanced esophago-gastric carcinomas(52). 
A comprehensive assessment of genetic alterations in cancers from patients in the LOGiC trial would potentially provide important information about co-occurring alterations associated with HER2 amplification and lack of treatment response.
In summary, HER2 status determined by IHC and FISH was highly correlated in UGI cancers. The prevalence of HER2 gene amplification was slightly higher in UGI cancers from men compared to women and was also higher among older patients. HER2 genomic heterogeneity was relatively infrequent, approximately 1.6% overall. The level of HER2 amplification was also correlated with responsiveness to lapatinib treatment in UGI cancer patients. *Of 1995 cases centrally assessed for HER2 status, a FISH result was not available for analysis in188 of the cases. **P-value was determined using Chi-sqare statistical test. It should also be noted that many Asian sites used a local laboratory, e.g. in China, and provided tissue sections in the central laboratory only for confirmation of their status (primary efficacy population) after accrual to the trial (see Figure 1A) . NA, not available. Figure 1A ). **Analyses for participants from the rest of the world and participants >60 years of age are included in Supplementary Table S6 . HR, hazard ratio; PEP, primary efficacy population; ITTP, intent to treat population. Supplementary Table   S4 ). 1 One case was excluded as no tumor tissue was identified; sufficient variability in HER2 immunostaining was noted in 17 cases to suggest the possibility of "HER2 genomic heterogeneity". 
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